Curative Biotechnology (CUBT) Osake Kurssi

Curative Biotechnology, Inc. engages in the provision of software solutions for the healthcare market. The company is headquartered in Boca Raton, Florida and currently employs 4 full-time employees. The company went IPO on 2001-07-11. The firm is identifying, acquiring, and developing disease modifying therapeutic drug candidates with a concentration on rare disease indications. The company has ongoing programs in three different therapeutic areas: degenerative eye disease, infectious disease, and neuro oncology. The company is focused on its degenerative eye disease platform. The first therapeutic to be developed on this platform is a Metformin Reformulation targeting the treatment of intermediate and late-stage age-related macular degeneration (AMD) disease. Its pipeline products include IMT504, CURB906, Metformin Reformulation, and COVID Vaccine with IMT504 Adjuvant. IMT504 is an immunotherapy for late-stage symptomatic rabies. CURB906 is a humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor cancer site to kill the tumor by inhibiting tumor growth and migration of the tumor.